Ali Khademhosseini

Ali Khademhosseini is currently the CEO and Founding Director at the Terasaki Institute for Biomedical Innovation. Previously, he was a Professor of Bioengineering, Chemical Engineering and Radiology at the University of California-Los Angeles (UCLA). He joined UCLA as the Levi Knight Chair in November 2017 from Harvard University, where he was a Professor at Harvard Medical School (HMS) and a faculty at the Harvard-MIT’s Division of Health Sciences and Technology (HST), Brigham and Women’s Hospital (BWH) and as well as associate faculty at the Wyss Institute for Biologically Inspired Engineering. His research interest is focused on combining micro- and nanoengineering approaches with advanced biomaterials for regenerative medicine applications. 

Dr. Khademhosseini has served as an Associate Editor for ACS Nano from 2013 to 2021. He is a fellow of the American Institute of Medical and Biological Engineering (AIMBE), Biomedical Engineering Society (BMES), Royal Society of Chemistry (RSC), Biomaterials Science and Engineering (FBSE), Materials Research Society (MRS), and American Association for the Advancement of Science (AAAS). He is also the recipient of the Mustafa Prize and is a member of the International Academy of Medical and Biological Engineering, the Royal Society of Canada, the Canadian Academy of Engineering, and the National Academy of Inventors.  

He is an author on >750 peer-reviewed journal articles, editorials, and review papers, >70 book chapters/edited books, and >50 patents/patent applications. He has been cited >137,100 times and has an H-index of 190. He has founded 3 companies, including Obsidio Medical, which was acquired by Boston Scientific.